<code id='94CD0290D5'></code><style id='94CD0290D5'></style>
    • <acronym id='94CD0290D5'></acronym>
      <center id='94CD0290D5'><center id='94CD0290D5'><tfoot id='94CD0290D5'></tfoot></center><abbr id='94CD0290D5'><dir id='94CD0290D5'><tfoot id='94CD0290D5'></tfoot><noframes id='94CD0290D5'>

    • <optgroup id='94CD0290D5'><strike id='94CD0290D5'><sup id='94CD0290D5'></sup></strike><code id='94CD0290D5'></code></optgroup>
        1. <b id='94CD0290D5'><label id='94CD0290D5'><select id='94CD0290D5'><dt id='94CD0290D5'><span id='94CD0290D5'></span></dt></select></label></b><u id='94CD0290D5'></u>
          <i id='94CD0290D5'><strike id='94CD0290D5'><tt id='94CD0290D5'><pre id='94CD0290D5'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:8967
          dose of methadone
          A dose of methadone Kevin D. Liles/AP

          The federal government is reforming methadone care for the first time in over two decades. But how far do the changes actually go?

          To many methadone clinics, the Biden administration’s recent refresh of the rules governing opioid treatment programs represents an unprecedented opportunity to offer care that is more compassionate and responsive to patients’ needs. To many patient advocates, however, it simply nibbles around the edges. 

          advertisement

          The reality is likely somewhere in between: It will depend, in large part, on whether state-level regulators embrace the changes, and whether individual clinics actually implement them. In reform-oriented states, and at patient-centered clinics, the new rules could make a world of difference for people seeking addiction treatment. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Readout Newsletter: Bristol, Sangamo, Gilead, and more

          EricRisberg/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl